Analysts Offer Predictions for Immatics FY2025 Earnings

Immatics (NASDAQ:IMTXFree Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Immatics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.34) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.79) per share.

A number of other equities analysts have also commented on IMTX. Piper Sandler initiated coverage on Immatics in a report on Monday, October 7th. They issued an “overweight” rating and a $19.00 price target for the company. Bank of America cut their target price on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 19th. Finally, The Goldman Sachs Group upgraded Immatics to a “strong-buy” rating in a research report on Monday, November 25th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $16.67.

View Our Latest Report on IMTX

Immatics Trading Up 0.9 %

Immatics stock opened at $5.40 on Wednesday. The firm has a 50 day simple moving average of $7.28 and a 200 day simple moving average of $9.78. Immatics has a 1-year low of $5.28 and a 1-year high of $13.77. The firm has a market capitalization of $644.54 million, a price-to-earnings ratio of -8.18 and a beta of 0.77.

Institutional Investors Weigh In On Immatics

Large investors have recently added to or reduced their stakes in the business. Quarry LP raised its holdings in shares of Immatics by 29.4% in the 3rd quarter. Quarry LP now owns 11,000 shares of the company’s stock valued at $126,000 after acquiring an additional 2,500 shares in the last quarter. AlphaCentric Advisors LLC increased its position in shares of Immatics by 25.0% in the third quarter. AlphaCentric Advisors LLC now owns 25,000 shares of the company’s stock worth $285,000 after purchasing an additional 5,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Immatics in the third quarter valued at approximately $114,000. Forefront Analytics LLC bought a new stake in Immatics during the second quarter valued at approximately $139,000. Finally, The Manufacturers Life Insurance Company grew its stake in Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock worth $1,880,000 after buying an additional 13,997 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Recommended Stories

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.